Systemic abnormalities in liver disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 24

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

494

HTML

6554

Figures (1-1)

206

Tables (1-3)

158

Sum=7412

Jun 28, 2009 (publication date) through Aug 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jun 28, 2009; 15(24): 2960-2974
Published online Jun 28, 2009. doi: 10.3748/wjg.15.2960

Table 3 Drugs that may need to be administered at reduced doses in patients with liver cirrhosis[187]

Drugs with high first-pass effect	Drugs metabolized mainly by
Drugs with high first-pass effect	CYP 1A2	CYP3A4	CYP2C9
Amitriptyline	Acetaminophen	Quinidine	Diclofenac
Bromocriptine	Caffeine	Amiodarone	Ibuprofen
Diltiazem	Mexiletine	Lidocaine	Mefenamic acid
Flumazenil	(R)-Warfarin	Midazolam	Tolbutamide
Fluorouracil	Imipramine	Diazepam	Phenytoin
Imipramine	Theophylline	Amitriptyline	Phenobarbital
Isosorbide dinitrate	Propranolol	Imipramine	(S)-Warfarin
Labetalol	Tamoxifen	Carbamazepine	Losartan
Lidocaine	Estradiol	(R)-Warfarin	Piroxicam
Morphine		Erythromycin
Nifedipine		Clarithromycin
Pentazocine
Propranolol
Verapamil

Citation: Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009; 15(24): 2960-2974
URL: https://www.wjgnet.com/1007-9327/full/v15/i24/2960.htm
DOI: https://dx.doi.org/10.3748/wjg.15.2960